4F-MABP: 4F-MABP is a little-studied fluorinated analogue of buphedrone first identified on the European NPS market in 2014. Animal data and seizure analyses show it acts as a dopamine and norepinephrine reuptake inhibitor comparable in potency to flephedrone. Human reports are scarce; effects resem
Related pages